{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:59:20Z","timestamp":1785772760990,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cardiovascular adverse events (CVAE) are clinically relevant side effects during treatment with the proteasome inhibitor carfilzomib. We investigated the predictive value of cardiac biomarkers for onset of CVAE in patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib, lenalidomide, and dexamethasone in the GMMG-CONCEPT study (NCT03104842). <\/jats:p>\n          <jats:p> Patients included in this prospective, multicenter correlative study were eligible if a serum sample before treatment initiation and at\u2009\u2265\u20091 later study time point were available. N-terminal pro-b-type natriuretic peptide (NT-proBNP) and high-sensitive Troponin I (hsTropI) were measured using immunoassays. Time-to-event analyses were performed using Kaplan\u2013Meier estimators and log-rank test was used for statistical analysis. Among 126 patients included in this study, 40 reported incident CVAE. No significant differences were observed for age, sex, cardiovascular risk factors and cardiovascular comorbidities between patients who experienced CVAE compared to patients without CVAE. NT-proBNP levels were elevated at baseline in 96 (76%) patients. Neither baseline levels nor change in NT-proBNP level during early induction cycles were predictive for the occurrence of CVAE. In contrast, elevation of hsTropI above the 99th percentile was rare. Patients with hsTropI level\u2009\u2265\u20092.9 ng\/L, corresponding to the lower limit of quantification, showed a higher risk for CVAE compared to patients with hsTropI\u2009&lt;\u20092.9 ng\/L at baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.0023). <\/jats:p>\n          <jats:p> In conclusion, in patients with newly diagnosed high-risk multiple myeloma undergoing carfilzomib-based quadruplet treatment, low hsTropI pretreatment levels are of high negative predictive value for the occurrence of CVAE whereas elevated NT-proBNP levels are very common before treatment initiation.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1186\/s40959-025-00358-x","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:50:11Z","timestamp":1751532611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Lisa B.","family":"Leypoldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"G\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon-Dschun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"Graeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Peceny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Dieing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Twerenbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Beitzen-Heineke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"358_CR1","first-page":"e528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.","journal-title":"Hemasphere"},{"issue":"3","key":"358_CR2","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105\u201318.","journal-title":"Lancet Oncol"},{"issue":"10245","key":"358_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"Lancet"},{"issue":"10292","key":"358_CR4","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"issue":"5","key":"358_CR5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"10","key":"358_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337.","journal-title":"Lancet Oncol"},{"issue":"13","key":"358_CR7","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383\u201391.","journal-title":"Cancer Res"},{"issue":"1","key":"358_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338.","journal-title":"Lancet Oncol"},{"issue":"2","key":"358_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"11","key":"358_CR10","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59(11):2557\u201369.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"358_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5(1):1\u201321.","journal-title":"JACC CardioOncol"},{"key":"358_CR12","doi-asserted-by":"crossref","unstructured":"Astarita A, Mingrone G, Airale L, Cesareo M, Colomba A, Catarinella C, et al. carfilzomib-based regimen and cardiotoxicity in multiple myeloma: incidence of cardiovascular events and organ damage in carfilzomib-dexamethasone versus carfilzomib-lenalidomide-dexamethasone. A Real-Life Prospective Study. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030955"},{"issue":"11","key":"358_CR13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753\u201361.","journal-title":"Haematologica"},{"issue":"13","key":"358_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","volume":"2","author":"A Chari","year":"2018","unstructured":"Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials. Blood Adv. 2018;2(13):1633\u201344.","journal-title":"Blood Adv"},{"issue":"1","key":"358_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","volume":"286","author":"S Bringhen","year":"2019","unstructured":"Bringhen S, Milan A, D\u2019Agostino M, Ferri C, Wasch R, Gay F, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019;286(1):63\u201374.","journal-title":"J Intern Med"},{"issue":"22","key":"358_CR16","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37(22):1946\u201355.","journal-title":"J Clin Oncol"},{"issue":"11","key":"358_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"key":"358_CR18","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J. et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244. Erratum in: Eur Heart J. 2023;44(18):1621. https:\/\/doi.org\/10.1093\/eurheartj\/ehad196. PMID: 36017568.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"358_CR19","doi-asserted-by":"publisher","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C. et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2024;42(1):26\u201337. https:\/\/doi.org\/10.1200\/JCO.23.01696. Epub 27 Sep 2023. PMID: 37753960; PMCID: PMC10730063.","DOI":"10.1200\/JCO.23.01696"},{"issue":"3","key":"358_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","volume":"36","author":"LB Leypoldt","year":"2022","unstructured":"Leypoldt LB, Besemer B, Asemissen AM, Hanel M, Blau IW, Gorner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885\u20138.","journal-title":"Leukemia"},{"issue":"36","key":"358_CR21","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"8","key":"358_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35(8):878\u201384.","journal-title":"J Clin Oncol"},{"issue":"7","key":"358_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.122.059678","volume":"146","author":"Y Sandoval","year":"2022","unstructured":"Sandoval Y, Apple FS, Mahler SA, Body R, Collinson PO, Jaffe AS, et al. High-sensitivity cardiac troponin and the 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guidelines for the evaluation and diagnosis of acute chest pain. Circulation. 2022;146(7):569\u201381.","journal-title":"Circulation"},{"issue":"22","key":"358_CR24","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749\u201354.","journal-title":"Circulation"},{"key":"358_CR25","doi-asserted-by":"crossref","unstructured":"Astarita A, Mingrone G, Airale L, Vallelonga F, Covella M, Catarinella C, et al. Multiple Myeloma patients undergoing carfilzomib: development and validation of a risk score for cardiovascular adverse events prediction. Cancers (Basel). 2021;13(7).","DOI":"10.3390\/cancers13071631"},{"issue":"3","key":"358_CR26","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519.","journal-title":"JAMA Oncol"},{"issue":"2","key":"358_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"358_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953\u201364.","journal-title":"Lancet Oncol."},{"issue":"1","key":"358_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ejh.12677","volume":"97","author":"S Danhof","year":"2016","unstructured":"Danhof S, Schreder M, Rasche L, Strifler S, Einsele H, Knop S. \u201cReal-life\u201d experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97(1):25\u201332.","journal-title":"Eur J Haematol"},{"issue":"2","key":"358_CR30","first-page":"83","volume":"7","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, et al. Cardiovascular safety in oncology clinical trials. JACCCardioOncol. 2025;7(2):83\u201395.","journal-title":"JACCCardioOncol"},{"issue":"5","key":"358_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cardfail.2020.07.006","volume":"27","author":"MR Rahman","year":"2021","unstructured":"Rahman MR, Ball S, Paz P, Elmassry M, Vutthikraivit W, Bandyopadhyay D, et al. Heart failure with carfilzomib in patients with multiple myeloma: a meta-analysis of randomized controlled trials. J Card Fail. 2021;27(5):610\u20132.","journal-title":"J Card Fail"},{"issue":"1","key":"358_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","volume":"13","author":"CR Tan","year":"2023","unstructured":"Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023;13(1):112.","journal-title":"Blood Cancer J"},{"issue":"3","key":"358_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/chf.12018","volume":"19","author":"J Popat","year":"2013","unstructured":"Popat J, Rivero A, Pratap P, Guglin M. what is causing extremely elevated amino terminal brain natriuretic peptide in cancer patients? Congest Heart Fail. 2013;19(3):143\u20138.","journal-title":"Congest Heart Fail"},{"issue":"6","key":"358_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1751-7133.2011.00258.x","volume":"18","author":"A Andreu","year":"2012","unstructured":"Andreu A, Guglin M. Exaggerated NT-proBNP production in patients with hematologic malignancies: a case series. Congest Heart Fail. 2012;18(6):333\u20136.","journal-title":"Congest Heart Fail"},{"issue":"4","key":"358_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.yjmcc.2004.01.001","volume":"36","author":"KK Ma","year":"2004","unstructured":"Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004;36(4):505\u201313.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"358_CR36","doi-asserted-by":"publisher","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","volume":"13","author":"H Fish-Trotter","year":"2020","unstructured":"Fish-Trotter H, Ferguson JF, Patel N, Arora P, Allen NB, Bachmann KN, et al. Inflammation and Circulating Natriuretic Peptide Levels. Circ Heart Fail. 2020;13(7):e006570.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"358_CR37","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1038\/bcj.2014.93","volume":"5","author":"S Atrash","year":"2015","unstructured":"Atrash S, Tullos A, Panozzo S, Bhutani M, Van Rhee F, Barlogie B, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5(1):e272.","journal-title":"Blood Cancer J"},{"issue":"26","key":"358_CR38","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"358_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"P Hagen","year":"2022","unstructured":"Hagen P, Zhang J, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12(5):83.","journal-title":"Blood Cancer J"},{"issue":"3","key":"358_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.16793","volume":"193","author":"C Bygrave","year":"2021","unstructured":"Bygrave C, Pawlyn C, Davies F, Craig Z, Cairns D, Hockaday A, et al. Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. Br J Haematol. 2021;193(3):551\u20135.","journal-title":"Br J Haematol"},{"issue":"1","key":"358_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):83.","journal-title":"Blood Cancer J"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:50:12Z","timestamp":1751532612000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00358-x","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki; all patients provided written informed consent and competent authorities and ethics committees approved the trial as well as this correlative study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Lisa B. Leypoldt: Advisory Role and Personal Fees: Adaptive, AbbVie, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi, Takeda Research Funding: AbbVie, GlaxoSmithKline Travel Support: Oncopeptides, Sanofi. Linlin Guo: nothing to disclose. Britta Besemer: Honoraria: Amgen, GlaxoSmithKline, Janssen, Oncopeptides, Pfizer, Sanofi. Mathias H\u00e4nel: Personal Fees: Falk Foundation, Gilead Sciences, Novartis, Sobi Advisory Role: Amgen, Bristol Myers Squibb\/Celgene, Gilead Sciences, Incyte, Janssen, Novartis, Pfizer, Roche, Sanofi\/Aventis, Sobi. Marc S. Raab: Consulting or Advisory Role: AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda Research Funding: Bristol Myers Squibb, Heidelberg Engineering, Janssen, Sanofi Travel: Amgen, Bristol Myers Squibb, Janssen Honoraria: AbbVie, Bristol Myers Squibb, Janssen, Sanofi. Christoph Mann: Honoraria: Bristol Myers Squibb\/Celgene, Sanofi. Christian S. Michel: Consulting or Advisory Role: Bristol Myers Squibb, Janssen, Oncopeptides Honoraria and Travel support: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Pfizer. Hans Christian Reinhardt: Personal Fees: AbbVie, Merck, Roche, Lilly, BMS, Janssen Grants: Gilead Sciences, AstraZeneca Other: CDL Therapeutics. Igor Wolfgang Blau: Nothing to disclose. Martin G\u00f6rner: Nothing to disclose. Yon-Dschun Ko: Nothing to disclose. Maike de Wit: Honoraria: Janssen. Hans Salwender: Personal Fees: AbbVie, Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Oncopeptides, Sanofi, Takeda, Pfizer, Stemline. Christof Scheid: Personal Fees: Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Sanofi, Takeda Research Support: Janssen, Takeda Ullrich Graeven Personal Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fujifilm, Ipsen, Johnson & Johnson, MSD Oncology, Novartis, Sanofi Aventis Advisory Role: Amgen, MSD Oncology Stock Ownership: BioNTech Research Funding: Ipsen, MacroGenics Nonfinancial Support: Boehringer Ingelheim, GlaxoSmithKline. Rudolf Peceny: Grants and Personal Fees: Sanofi Genzyme Grants: Boehringer Ingelheim, Bristol Myers Squibb\/Celgene, DRK Blutspendedienst NSTOB, Novartis. Peter Staib: Grants, Personal Fees, Nonfinancial Support, and Other: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Incyte, Janssen-Cilag, Novartis, Pfizer, Roche, Takeda. Annette Dieing: Advisory Boards: Bristol Myers Squibb. Hartmut Goldschmidt: Grants: Amgen, Array Biopharma\/Pfizer, BMS\/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi. Research Funding: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis Honoraria: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, Travel Support: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer. Carsten Bokemeyer: Honoraria: AOK Germany, AstraZeneca, Bayer, Berlin Chemie, Bristol Myers Squibb, GSO Research Organisation, Janssen-Cilag, med update, Merck Serono, Merck Sharp & Dohme, Novartis, Roche, Sanofi Aventis. Tanja Zeller: Tanja Zeller is supported by the German Research Foundation, the EU Horizon 2020 programme, the EU ERANet and ERAPreMed Programmes, the German Center for Cardiovascular Research (DZHK e.V., 81Z0710102) and the German Ministry of Education and Research. Tanja Zeller and Raphael Twerenbold are listed as co-founders and shareholders of the ART-EMIS Hamburg GmbH, which holds an international patent application on the use of a computing device to estimate the probability of myocardial infarction (International Publication Numbers WO2022043229A1, TW202219980A). Raphael Twerenbold: Raphael Twerenbold reports research support from the German Center for Cardiovascular Research (DZHK), the K\u00fchne Foundation, the Joachim Herz Foundation, the Swiss National Science Foundation and the Swiss Heart Foundation as well as speaker honoraria\/consulting honoraria from Abbott, Amgen, Astra Zeneca, Psyros, Roche, Siemens, Singulex and Thermo Scientific BRAHMS. Dirk Westermann: Nothing to disclose. Katja C. Weisel: Honoraria: AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Roche, Sanofi, Takeda Research Funding: AbbVie, Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Sanofi. Antonia Beitzen-Heineke:,Travel Support: Octapharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}